SAMT ETF Analysis: The Advisorsa Inner | NYSE
Large Blend | NYSE, USA | Market Cap: 801m USD | 12M Return: 16.2% | US00775Y6453 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.52M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 4.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The Advisors Inner Circle Fund III (NYSE: SAMT) is an actively-managed ETF that invests primarily in U.S. common stocks selected for their correlation to broad macroeconomic themes, as identified by its adviser, Strategas Asset Management, LLC. The fund maintains flexibility across market capitalizations but applies liquidity screening criteria to potential holdings.
The fund launched on January 25, 2022, with approximately $745 million in assets and is classified within the Large Blend category, indicating its underlying portfolio is oriented toward larger U.S. issuers with a mix of growth and value characteristics. As a thematic ETF, SAMT employs a top-down investment approach that seeks to capitalize on secular trends such as demographic shifts, technological innovation, or policy developments, distinguishing it from passive index-tracking funds. Strategas Asset Management is a research-driven firm known for its macroeconomic and policy analysis, which informs the funds stock-selection process.
- Strategas macro-thematic ETF assets under management accelerate past $1 billion
- Active strategy underperforms passive large-blend peers during sector rotation
- Fee pressure intensifies as competitor thematic ETFs launch at lower expense ratios
As of September 27, 2026, the stock is trading at USD 42.32 with a total of 65,265 shares traded. Over the past week, the price has changed by +0.52%, over one month by -1.99%, over three months by -6.85% and over the past year by +16.21%.
Current recommended Stop Loss: 41.40 (which is 2.2% or 2.1 ATR below the current price).
The Advisorsa Inner has no consensus analysts rating.